Typhoid Fever – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever – Drugs in Development, 2021, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 2, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 2 and 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Enesi Pharma Ltd

Etna Biotech Srl

Eubiologics Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Matrivax Research & Development Corp

Novo Medi Sciences Pvt Ltd

Prokarium Ltd

Protein Potential LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Typhoid Fever - Overview

Typhoid Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Typhoid Fever - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Typhoid Fever - Companies Involved in Therapeutics Development

Enesi Pharma Ltd

Etna Biotech Srl

Eubiologics Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Matrivax Research & Development Corp

Novo Medi Sciences Pvt Ltd

Prokarium Ltd

Protein Potential LLC

Sanofi Pasteur SA

Shantha Biotechnics Pvt Ltd

Walvax Biotechnology Co Ltd

Typhoid Fever - Drug Profiles

(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(paratyphoid + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(shigella + typhoid) (Bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Streptococcal pneumonia + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhella - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ViCRM-197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhoid Fever - Dormant Projects

Typhoid Fever - Discontinued Products

Typhoid Fever - Product Development Milestones

Featured News & Press Releases

Dec 17, 2020: IVI-SK’s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Sep 17, 2020: Typhoid: Study confirms Vi-DT conjugate vaccine is safe and immunogenic in children 6-23 months of age

Jul 14, 2020: Prokarium obtains notice of allowance for US patent covering the modification of an attenuated strain of salmonella enterica serovar typhi to develop a vaccine against enteric fever

Nov 26, 2019: Prokarium announces MHRA acceptance to run phase i trial of lead vaccine against enteric fever

Oct 08, 2019: Prokarium secures £4.6M from Wellcome to fund the clinical development of its lead vaccine programme

Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification

Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine

Jun 23, 2011: Sanofi Pasteur’s Typhim Vi Receives Prequalification From World Health Organization

Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate

Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine

Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine

Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study

Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Typhoid Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Typhoid Fever – Pipeline by Enesi Pharma Ltd, 2021

Typhoid Fever – Pipeline by Etna Biotech Srl, 2021

Typhoid Fever – Pipeline by Eubiologics Co Ltd, 2021

Typhoid Fever – Pipeline by GlaxoSmithKline Plc, 2021

Typhoid Fever – Pipeline by Indian Immunologicals Ltd, 2021

Typhoid Fever – Pipeline by Matrivax Research & Development Corp, 2021

Typhoid Fever – Pipeline by Novo Medi Sciences Pvt Ltd, 2021

Typhoid Fever – Pipeline by Prokarium Ltd, 2021

Typhoid Fever – Pipeline by Protein Potential LLC, 2021

Typhoid Fever – Pipeline by Sanofi Pasteur SA, 2021

Typhoid Fever – Pipeline by Shantha Biotechnics Pvt Ltd, 2021

Typhoid Fever – Pipeline by Walvax Biotechnology Co Ltd, 2021

Typhoid Fever – Dormant Projects, 2021

Typhoid Fever – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Typhoid Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports